Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: Randomized comparison of three regimens

Journal of Dermatological Treatment

Volumn 23, Issue 3, 2012, Pages 177-183

  Kelekci, Kiymet Handan ^a   Kelekci, Sefa ^a   Yengel, Irem ^a   Gul, Sule ^a   Yilmaz, Bulent ^a  

^a Numune Education and Research Hospital   (Turkey)

Author keywords

Combined oral contraceptives; Cyproterone acetate; Drospirenone; Hirsutism; Polycystic ovary syndrome; Spironolactone

Indexed keywords

CYPROTERONE ACETATE; DROSPIRENONE PLUS ETHINYLESTRADIOL; SPIRONOLACTONE;

ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HIRSUTISM; HUMAN; MAJOR CLINICAL STUDY; MODIFIED FERRIMAN GALLWEY HIRSUTISM SCORE; NAUSEA; OLIGOMENORRHEA; ORAL CONTRACEPTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SPOTTING; VOMITING;

ADOLESCENT; ADULT; ALDOSTERONE ANTAGONISTS; ANDROGEN ANTAGONISTS; ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; CYPROTERONE ACETATE; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HIRSUTISM; HUMANS; SEVERITY OF ILLNESS INDEX; SPIRONOLACTONE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84861030485     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2010.519766     Document Type: Article

References (20)

1. Falsetti L, Gambera A, Platto C, Legrenzi L. Management of hirsutism. Am J Clin Dermatol. 2000; 1: 89-99.
2. Azziz R. The evaluation and management of hirsutism. Obstet Gynecol. 2003; 101: 995-1007. (Pubitemid 36561267)
3. Wong IL, Morris RS, Chang L, Spahn MA, Stanczyk FZ, Lobo RA. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab. 1995; 80: 233-238.
4. Erenus M, Yucelten D, Gurbuz O, Durmusoglu F, Pekin S. Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. Fertil Steril. 1996; 66: 216-219. (Pubitemid 26244451)
5. Mowszowicz I, Wright F, Vincens M, Rigaud C, Nahoul K, Mavier P, et al. Androgen metabolism in hirsute patients treated with cyproterone acetate. J Steroid Biochem. 1986; 20: 757-761.
6. Marcondes JA, Waychenberg BL, Abujamra AG, Luthold WW, Samojlik E, irschner MA. Monthly cyproterone acetate in the treatment of hirsute women: Clinical and laboratory effects. Fertil Steril. 1990; 53: 40-44. (Pubitemid 20041313)
7. Kelestimur F, Sahin H. Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism. Fertil Steril. 1998; 69: 66-69. (Pubitemid 28072994)
8. Hatch R, Rosenfield RL, Kim MH, Teadway D. Hirsutism: Implications, etiology and management. Am J Obstet Gynecol. 1981; 140: 815-830.
9. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81: 19-25.
10. Yildiz BO. Assessment, diagnosis and treatment of a patient with hirsutism. Nat Clin Pract Endocrinol Metab. 2008; 4: 294-300. (Pubitemid 351571140)
11. Claman P, Graves GR, Kredentser JV, Sagle MA, Tan S, Tummon I, Fluker M; Reproductive Endocrinology Infertility Committee and Executive Committeee and Council, Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guidelines. Hirsutism: evaluation and treatment. J Obstet Gynaecol Can. 2002; 24: 62-73, 77-9.
12. Calaf J, Lopez E, Millet A, Alcaniz J, Fortuny A, Vidal O, et al. Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: A 12-month, double-blind, parallel clinical trial. J Clin Endocrinol Metab. 2007; 92: 3446-3452. (Pubitemid 47435318)
13. Batukan C, Muderris I. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril. 2005; 85: 436-440.
14. Ibanez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide- metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: Opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab. 2004; 89: 1592-1597. (Pubitemid 38507907)
15. Lanzone A. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: A clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab. 2004; 89: 2817-2823. (Pubitemid 38766371)
16. Krattenmacher R. Drospirenone: Pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000; 62: 29-38.
17. Porcile A, Gallardo E. Long-term treatment of hirsutism desogestrel compared with cyproterone acetate in oral contraceptives. Fertil Steril. 1991; 55: 877-881.
18. Falsetti L, Ramazzotto F, Rosina B. Efficacy of combined ethinyloestradiol (0.035 mg) and cyproterone acetate (2 mg) in acne and hirsutism in women with polycystic ovary syndrome. J Obstet Gynaecol. 1997; 17: 565-568. (Pubitemid 28010363)
19. Grigoriou O, Papadias C, Konidaris S, Antoniou G, Karakitsos P, Giannikos L. Comparison of flutamide and cyproterone acetate in the treatment of hirsutism: A randomized controlled trial. Gynecol Endocrinol. 1996; 10: 119-123. (Pubitemid 26148374)
20. Jasonni VM, Bulletti C, Naldi S, Di Cosmo E, Cappuccini F, Flamigni C. Treatment of hirsutism by an association of oral cyproterone acetate and transdermal 17b-estradiol. Fertil Steril. 1991; 55: 742-745.